10-Q: Vitro BioPharma Faces Going Concern Amidst Q1 Losses

Vitro BioPharma reported a reduced net loss in Q1 2026 but continues to face substantial doubt about its ability to continue as a going concern due to significant working capital deficit and reliance on future capital raises.

Summary

• Reported a net loss of $1,106,968 for the three months ended January 31, 2026, a 61% decrease from the $2,834,662 loss in the prior year period.
• Total revenue increased by 18% to $529,417 for the three months ended January 31, 2026, up from $449,874 in the same period last year.
• Sales of AlloRx Stem Cells to foreign third-party clinics increased by 36% to $384,276, driven by increased patient treatments.
• Research and development product sales decreased by 11% to $98,955, attributed to fewer purchases of CAFs and native fibroblasts by institutions.
• Selling, General and Administrative (SG&A) expenses decreased by 37% to $1,334,975, primarily due to a $597,853 reduction in consulting fees.
• Research and Development (R&D) expenses increased by 129% to $169,221 as the company prepares for future clinical trials.
• Incurred an impairment expense of $99,700 due to a failed production batch of AlloRx.
• Interest expense surged by 385% to $502,730, mainly due to debt discount accretion costs related to the 2025 Senior Secured Notes.
• Recognized a $300,000 gain on forgiveness of debt from a vendor credit.
• Cash balance decreased by 18.4% from $604,183 at October 31, 2025, to $492,923 at January 31, 2026.
• Net cash used in operating activities increased by 159% to $1,108,396.
• Working capital deficit improved slightly by $0.3 million to approximately $4.5 million as of January 31, 2026.
• Issued 50,000 shares of Series A-1 Convertible Preferred Stock for $1,000,000 in proceeds during the quarter.
• Disclosure controls and procedures were deemed not effective due to ineffective internal control over financial reporting.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with low sentiment due to the explicit 'going concern' warning, significant cash burn from operations, and the acknowledged ineffectiveness of internal controls, despite a reduction in net loss primarily driven by non-recurring factors from the prior year.

Positives

• Net loss significantly decreased by 61% to $1.1 million for the quarter, primarily due to lower consulting costs and the absence of a large debt extinguishment loss from the prior year.
• Total revenue increased by 18% year-over-year, driven by a 36% increase in AlloRx Stem Cell sales to foreign third-party clinics.
• SG&A expenses decreased substantially by 37%, indicating cost management efforts, particularly in consulting fees.

Negatives

• The company continues to operate with a substantial working capital deficit of approximately $4.5 million as of January 31, 2026.
• Cash used in operating activities increased significantly by 159% to $1.1 million, indicating a higher cash burn rate.
• Interest expense increased by 385% to $502,730, largely due to debt discount accretion on new senior secured convertible notes.
• An impairment expense of $99,700 was recorded due to a failed production batch of AlloRx, impacting gross profit.
• Research and Development expenses increased by 129%, which, while strategic, contributes to the overall cash burn without immediate revenue generation.
• Disclosure controls and procedures were concluded to be not effective due to ineffective internal control over financial reporting.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to accumulated deficit, recurring net losses, and insufficient working capital.
• The company's ability to fund operations and commence planned clinical trials is dependent on raising additional capital through debt or equity financings, which is not assured.
• Future equity or debt financings may dilute existing stockholders' ownership interests or impose restrictive covenants.
• Relinquishing valuable rights to technologies or product candidates may be necessary if funds are raised through collaborations or licensing arrangements.
• The successful development of product candidates is highly uncertain and subject to numerous risks, making it difficult to estimate the timing and costs for regulatory approval.
• Fluctuations in sales volumes of research and development products can occur as sales are on a purchase order basis without minimum purchase obligations.

Future Outlook

The company expects SG&A expenses to increase with future headcount to support increased R&D activities and public company compliance costs. R&D expenses are projected to rise significantly as clinical trials commence and programs advance. AlloRx Stem Cell sales internationally are anticipated to increase over the next year. The company needs $4 million to $6 million to commence planned Phase 1/2a clinical trials for PTHS and Long COVID and has extended the maturity date of its 2025 Series Senior Secured Convertible Notes to February 27, 2027. Long-term capital requirements also include $0.3 million to $1.0 million for additional clean rooms for manufacturing.

Management Comments

• Management plans to address the going concern by raising additional capital through public and/or private offerings of equity securities and potentially issuing additional debt instruments.
• Management has various initiatives underway to increase revenue generation through diversified offerings of products and services related to its stem cell technology and analytical capabilities, aiming to achieve profitable operations as quickly as possible.
• Management states that the company does not anticipate commencing any clinical trials of its AlloRx Stem Cell therapy unless and until substantial additional capital is received.

Industry Context

StockSavvy.ai notes that Vitro BioPharma operates in the highly capital-intensive and risky biotechnology sector, specifically focusing on regenerative medicine, stem cell therapy for autoimmune and inflammatory disorders, and cosmeceuticals. The company's current stage, with planned Phase 1/2a clinical trials, is typical for early-stage biotech firms that require substantial funding for R&D and clinical development. The reliance on external capital and the significant accumulated deficit are common challenges in this industry, where commercialization success is uncertain and often years away. The increase in AlloRx Stem Cell sales to foreign clinics suggests a market for its current products, but the overall financial health indicates it is far from self-sustaining, aligning with the high burn rates seen in early-stage drug development.

Comparison to Industry Standards

• Vitro BioPharma's accumulated deficit of nearly $50 million and ongoing net losses are typical for early-stage biotechnology companies heavily invested in R&D, such as those developing novel cell therapies. For instance, many small-cap biotech firms like Athersys (ATHX) or Mesoblast (MESO) have reported significant losses for extended periods while advancing their stem cell programs.
• The 129% increase in R&D expenses is consistent with companies preparing for or initiating clinical trials, a critical phase for biotech firms. This is comparable to the R&D ramp-up seen in companies like Fate Therapeutics (FATE) or Sana Biotechnology (SANA) during their early clinical development stages.
• The substantial working capital deficit and explicit 'going concern' warning are common for pre-revenue or early-revenue biotech companies. This contrasts sharply with established pharmaceutical companies like Johnson & Johnson (JNJ) or Pfizer (PFE) which have robust cash flows and strong balance sheets.
• The reliance on convertible debt and preferred stock for financing, as evidenced by the issuance of Series A-1 Preferred Stock and various convertible notes, is a standard practice for early-stage biotech firms that lack access to traditional bank financing or large public equity offerings due to their risk profile. This is similar to financing strategies employed by numerous emerging biotech ventures.

Management Changes

Corporate Governance

Related Party Transactions

• Dr. Jack Zamora, former CEO and 29% stockholder, owed the company $2,250 in accounts receivable as of January 31, 2026. Product sales to Dr. Zamora's medical practice were $0 for the three months ended January 31, 2026, down from $15,750 in the prior year.
• The spouse of the Chief Science Officer leases office and lab space to the company at $5,645 per month, with the lease running through June 2030. No past due rent was owed as of January 31, 2026.
• The company owed its CEO, Christopher Furman, $22,610 in travel expense reimbursements and $970,000 in accrued, but unpaid, bonuses as of January 31, 2026.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity or convertible debt financings required to sustain operations and fund clinical trials.
• Shareholders are exposed to substantial risk due to the 'going concern' warning, indicating uncertainty about the company's long-term viability.
• Employees, particularly those in R&D, may experience increased workload and pressure as the company pushes for clinical trial commencement, but also face uncertainty given the company's financial position.
• Creditors holding convertible notes face risks related to the company's ability to repay or convert debt, especially given the high interest expense and ongoing losses.
• Customers of AlloRx Stem Cells and InfiniVive products may benefit from continued product availability and potential future therapeutic developments, but the company's financial instability could pose supply risks.
• Suppliers and vendors face credit risk due to the company's working capital deficit and reliance on future capital raises, although a $300,000 vendor credit was negotiated during the quarter.

Next Steps

• Raise additional capital through public/private equity or debt financings.
• Implement initiatives to increase revenue generation through diversified product and service offerings.
• Commence Phase 1/2a clinical trials for AlloRx Stem Cell therapy in PTHS and Long COVID, pending sufficient working capital.
• Expand the intellectual property portfolio.
• Hire additional personnel in research, manufacturing, regulatory, clinical development, and management.
• Seek regulatory approval for product candidates that successfully complete clinical development.
• Expand manufacturing capabilities, including potentially adding clean rooms (estimated cost $0.3M to $1.0M).
• Expand operational, financial, and management systems.

Key Dates

Recommendation

The company explicitly states 'substantial doubt about our ability to continue as a going concern' and that current cash is 'not sufficient to support our daily operations for the next 12 months.' This fundamental risk, coupled with a significant increase in cash used in operating activities, a large accumulated deficit, and ineffective internal controls, outweighs the reported reduction in net loss and revenue growth. The reliance on future, uncertain capital raises for survival and clinical trial commencement presents an extremely high-risk profile. A seasoned investor would view this as a distressed situation with a high probability of further dilution or financial instability.

Keywords

Biopharma, Stem Cell Therapy, AlloRx, Regenerative Medicine, Clinical Trials, SEC Filing, 10-Q, Financial Report, Going Concern, Convertible Notes, Warrants, Biotechnology, Autoimmune Diseases, Inflammatory Disorders, Cosmeceuticals, InfiniVive MD